Back

Severe Asthma Research Study

Official Title

A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of dexpramipexole administered orally for 52 weeks in participants with eosinophilic asthma (EXHALE-2)

Study Details

The purpose of this study is to assess the efficacy and safety of an oral medication in participants with inadequately controlled asthma and a history of exacerbations.

Principal Investigator

Dr. James Krings

IRB Number

202303198

Eligibility

1. Participants must be at least 18 years of age with asthma (treated with inhaled corticosteroid)
2. Participants must have had 2 asthma exacerbations in the last year requiring oral steroids or an emergency room visit
3. Participants must not smoke

Compensation is provided (contact the study team for compensation amount).

Volunteer Information

For more information about this study, contact Volunteer for Health at:

Back